Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
Active, not recruiting · NCT04616963 · Registry updated 2023-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis | AIDS, Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Slow Virus Diseases, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 4 | 2023-05-06 | NCT04616963 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of California, San Diego | 337 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UC San Diego AntiViral Research Center (AVRC) | San Diego | United States | 2 |